Fertility Test Market Analysis

End use Segment Analysis

By 2035, the home care settings segment is expected to attain the largest revenue share of 48.4% owing to the increased demand for convenient, non-invasive, and private fertility monitoring solutions. There has been an increased interest in tracking ovulation and sperm quality at home, which in turn boosts the adoption of these at-home testing devices. In addition, the e-commerce availability has also made these devices more accessible, solidifying home-based fertility care as a preferred choice for many users. In January 2026, Pulsenmore Ltd. announced that it entered into a commercial agreement with Clalit Health Services to provide its Pulsenmore FC at-home ultrasound solution for remote follicular monitoring in women undergoing IVF and fertility preservation. The deal was valued at USD 4.5 million over five years, following an 18-month pilot, and will operate through Beilinson NEXT, which is the virtual hospital at Beilinson Medical Center, offering patients real-time guidance and specialist oversight from home, hence denoting a wider segment scope in the market.

Sample Type Segment Analysis

By the conclusion of the forecast duration, the blood-based subtype is expected to lead this segment with a considerable share in the fertility test market. The higher accuracy, reliability, and ability to deliver proper hormonal insights when compared to other tests are the key factors behind this leadership.  Also, these blood-based tests measure key fertility-related hormones such as FSH, LH, AMH, estradiol, and progesterone, which are highly essential for evaluating ovarian reserve, ovulation cycles, and overall reproductive health. In this context, Sysmex Corporation in March 2024 announced that it had launched six new immunoassay kits in Japan, which include LH, FSH, estradiol, progesterone, prolactin, and testosterone, for gynecological and gonadal hormone testing. It also notes that these blood-based assays are compatible with the HISCL-series automated systems, enabling accurate hormone measurement, supporting the diagnosis and treatment of infertility and other gynecological disorders.

Application Segment Analysis

In terms of application, the female fertility testing is anticipated to garner a significant share over the forecasted years. The growing burden of conditions such as polycystic ovary syndrome (PCOS) and increased focus on female reproductive health are the key factors driving this leadership. Therefore, most of the national and national health surveys highlight that female reproductive health screening is common in pre-conception care. In this context, the statistically validated analysis by the World Health Organization in January 2026 reported that PCOS is a common hormonal disorder affecting 10% to 13% of reproductive-aged women, wherein up to 70% are undiagnosed worldwide. It causes irregular menstrual cycles, abnormal ovulation, infertility, excess hair growth, acne, and ovarian cysts, indicating a sustained demand in the market for women.

Our in-depth analysis of the fertility test market includes the following segments: